Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy S Bailey

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Journal of Diabetes Science and Technology|February 24, 2016
Fundamental Importance of Reference Glucose Analyzer Accuracy for Evaluating the Performance of Blood Glucose Monitoring Systems (BGMSs)Timothy S Bailey, Leslie J Klaff, Jane F Wallace, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Diabetes Care|January 25, 2017
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening InjectionsRichard M Bergenstal, Timothy S Bailey, David Rodbard, et al.
Diabetes, Obesity & Metabolism|November 11, 2018
Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3Riccardo C Bonadonna, Jean-François Yale, Claire Brulle-Wohlhueter, et al.
Journal of Diabetes Science and Technology|June 16, 2017
Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile DeviceTimothy S Bailey, Jane F Wallace, Scott Pardo, et al.
Endocrinology, Diabetes & Metabolism|November 22, 2021
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world studySean D Sullivan, Nick Freemantle, Rishab A Gupta, et al.
Diabetes Technology & Therapeutics|July 10, 2010
Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimenSteven V Edelman, Bruce W Bode, Timothy S Bailey, et al.
Diabetes Technology & Therapeutics|April 25, 2014
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensorTimothy S Bailey, Andrew Ahmann, Ronald Brazg, et al.
Current Medical Research and Opinion|May 1, 2010
Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetesLaurence J Hirsch, Michael A Gibney, John Albanese, et al.
Diabetes Technology & Therapeutics|November 18, 2017
The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed<sup>™</sup> 670G Hybrid Closed-Loop SystemToni L Cordero, Satish K Garg, Ronald Brazg, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Journal of Diabetes Science and Technology|February 24, 2016
Fundamental Importance of Reference Glucose Analyzer Accuracy for Evaluating the Performance of Blood Glucose Monitoring Systems (BGMSs)Timothy S Bailey, Leslie J Klaff, Jane F Wallace, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Diabetes Care|January 25, 2017
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening InjectionsRichard M Bergenstal, Timothy S Bailey, David Rodbard, et al.
Diabetes, Obesity & Metabolism|November 11, 2018
Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3Riccardo C Bonadonna, Jean-François Yale, Claire Brulle-Wohlhueter, et al.
Journal of Diabetes Science and Technology|June 16, 2017
Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile DeviceTimothy S Bailey, Jane F Wallace, Scott Pardo, et al.
Endocrinology, Diabetes & Metabolism|November 22, 2021
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world studySean D Sullivan, Nick Freemantle, Rishab A Gupta, et al.
Diabetes Technology & Therapeutics|July 10, 2010
Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimenSteven V Edelman, Bruce W Bode, Timothy S Bailey, et al.
Diabetes Technology & Therapeutics|April 25, 2014
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensorTimothy S Bailey, Andrew Ahmann, Ronald Brazg, et al.
Current Medical Research and Opinion|May 1, 2010
Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetesLaurence J Hirsch, Michael A Gibney, John Albanese, et al.
Diabetes Technology & Therapeutics|November 18, 2017
The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed<sup>™</sup> 670G Hybrid Closed-Loop SystemToni L Cordero, Satish K Garg, Ronald Brazg, et al.
Pageof 11